In this issue:
Immunotherapy + live bacterial supplementation in mRCC
Radiation necrosis after checkpoint inhibitors and radiosurgery for mRCC brain metastases
Sarcopenia and survival with organ-confined RCC after radical nephrectomy
Patterns of first-line targeted therapy in older adults with mRCC
Immune inactivation by CD47 in ccRCC
Stereotactic radiotherapy + pembrolizumab for oligometastatic RCC
Nivolumab + stereotactic radiotherapy in pre-treated mRCC
Incidence and distribution of new RCC cases
Sitravatinib + nivolumab in ccRCC
Proteogenomic analysis of ccRCC
Please login below to download this issue (PDF)